Frontier Biotechnologies Inc. Gets NMPA Approval for Phase II Study of Albuvirtide as HIV Therapy
Nanjing-based Frontier Biotechnologies Inc. (SHA: 688221) has received approval from the National Medical Products Administration...
SHA: 688221
Frontier Biotechnologies Partners with Yuyue Med for FB2001 Atomizer
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu...
Frontier Biotechnologies Partners with CASAPC for AIDS Prevention in China
China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced a collaboration agreement with the Chinese Association...
Frontier Biotechnologies Gains CDE Approval for FB2001 COVID-19 Inhalant Study
China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced receiving approval from the Center for Drug...
Frontier Biotech’s FB2001 Inhalant Accepted for NMPA Review
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced that a registrational clinical filing for its FB2001...
Frontier Biotech Partners with Kindstar to Boost Anti-Infection Testing, Especially for HIV
China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar...
Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced plans to raise RMB 270 million (USD 51.4...
Frontier Biotech’s Albuvirtide Shows Promising HIV Treatment Results in Phase III Trial
China-based Frontier Biotechnologies Inc. (SHA: 688221) has released Phase III trial data for albuvirtide, China’s...